The risk for acute kidney injury was not higher among patients with an eGFR dip at empagliflozin initiation. Previous studies have reported renal benefits with sodium glucose cotransporter 2 inhibitor ...

Please provide your email address to receive an email when new articles are posted on . Patients with an eGFR below the 25th percentile of distribution for their age and sex had greater risks for ...

Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared with ...

Uncommon EGFR mutations, such as exon 20 insertions, account for nearly one-third of EGFR-driven NSCLC, complicating treatment strategies due to their diversity and structural challenges. Traditional ...

Please provide your email address to receive an email when new articles are posted on . The paper provides a race-free equation to estimate kidney filtration in adults with stable kidney function. It ...

In December 2025, the FDA approved the subcutaneous (sub-Q) administration of a fixed combination of amivantamab (Rybrevant; ...

Treatment landscape of EGFR-mutant non–small cell lung cancer has evolved in the most recent years. In the metastatic setting, with combination approaches tested in first-line, whereas in the ...

Hello. It's Mark Kris, from Memorial Sloan Kettering. I'm about to say some things that will not make everyone happy. I would like to comment on a recently published article in The New England Journal ...

Figure 6: Mechanism of Anti-EGFR resistance in head and neck cancer by activation of TLR4-MyD88 signaling. EGFR inhibition by cetuximab prevents Src activation, thus preventing MyD88 degradation, ...

A retrospective analysis of 1,804 patients with NSCLC undergoing next-generation sequencing (NGS) in 2019-2024 at University Hospital Würzburg (single-center cohort, including 15 patients with ...